Please login to the form below

Not currently logged in


This page shows the latest Fanapt news and features for those working in and with pharma, biotech and healthcare.

FDA panel backs sleep pattern drug for blind

FDA panel backs sleep pattern drug for blind

Polymeropoulos. Vanda previously developed a schizophrenia treatment called Fanapt (iloperidone) which is licensed in North America to Novartis but has failed to make much headway in the market since its launch

Latest news

  • Vanda withdraws EU application for schizophrenia drug Vanda withdraws EU application for schizophrenia drug

    Despite the struggle for approval in the EU, the drug has been available for people with schizophrenia in the US since 2009, where it is sold under the brand name Fanapt.

  • Next generation

    Iloperidone. Fanapt (Novartis). Schizophrenia. US. Levodopa/benserazide. Co-Beneldopa (Teva Pharmaceuticals)  . Parkinson's disease.

  • US launch for Novartis' Fanapt

    Novartis has launched schizophrenia treatment Fanapt (iloperidone) in the US, for acute treatment of schizophrenia in adults. ... In clinical trials, Fanapt was shown to be effective for the symptoms of schizophrenia.

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...